Latest Regulatory News

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

St George Mining reports its thickest and highest-grade rare earth and niobium intercept to date at the Araxá Project, signaling a potential major resource expansion in Brazil.

BlinkLab Limited has appointed its Co-Founder and CEO, Dr Henk-Jan Boele, as Managing Director to steer the company through its pivotal FDA 510(k) trial for its autism diagnostic technology. The move coincides with key board changes and signals a strategic shift as BlinkLab prepares for early commercialisation.

Bendigo and Adelaide Bank has been hit with a $50 million operational risk capital charge by APRA, while AUSTRAC launches an enforcement investigation into serious AML/CTF breaches. The bank commits to intensifying risk management efforts amid regulatory scrutiny.

Renegade Exploration has secured an option to acquire the Rooster Hill Monazite Project in Wyoming, tapping into a historically promising rare earth element resource. The move expands Renegade’s US footprint amid rising demand for critical minerals.

Bio-Gene Technology reports promising progress on its US Department of Defense-funded insecticide projects, with early mosquito mortality evidence from its Flavocide wearable device and pending launch of its Qcide indoor spray program.

International Graphite Limited has secured development approval for its Collie graphite processing facility, marking a significant step toward integrated graphite production in Western Australia.

Lake Resources has secured a crucial environmental management plan approval for its Kachi Lithium Project, marking a significant step toward final environmental impact assessment clearance and sustainable lithium production.

Perpetual Limited has extended its exclusivity agreement with Bain Capital into early 2026 as discussions continue over the potential sale of its Wealth Management business. While progress is steady, no binding deal is yet assured.

Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.

RAS Technology Holdings will not renew its Complete Racing Solution contract with Stake in 2026, shifting focus to expanding in regulated markets and Asia’s burgeoning racing sector.

TrivarX Limited has reported compelling clinical trial results demonstrating its single-lead ECG algorithm’s high sensitivity in detecting major depressive episodes among US veterans, marking a significant step in objective mental health screening.